AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05418608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiotracer
Description: A novel SV2A imaging tracer which is used in conjunction with positron emission tomography scans.
Study NCT04730934 — intervention group
Intervention type: OTHER
Intervention: Perceived stress scale
Description: Perceived stress scale (PSS) : The PSS is a validated 10-item self-report questionnaire which asks individuals to indicate how often they have found their lives unpredictable, uncontrollable, and overloaded in the last month. The higher scores indicating greater perceived stress.
Study NCT04730934 — intervention group
Intervention type: OTHER
Intervention: Fibromyalgia impact questionnaire
Description: Fibromyalgia impact questionnaire (FIQ): The FIQ is composed of 10 items. The first item contains 11 questions related to physical functioning - each question is rated on a 4 point Likert type scale. Items 2 and 3 ask the patient to mark the number of days they felt well and the number of days they were unable to work (including housework) because of fibromyalgia symptoms. Items 4 through 10 are horizontal linear scales marked in 10 increments on which the patient rates work difficulty, pain, fatigue, morning tiredness, stiffness, anxiety and depression.
Study NCT04730934 — intervention group
Intervention type: OTHER
Intervention: The drugs used before and during the pandemic, the patient's job status, physical activity conditions, pain status
Description: Drug using: Antidepressant, SNRI, gabapentin, SSRI, myorelaxan, nsaid, paracetamol, pregabalin, tramadol, food supplement.~Job status: Participants were questioned about their occupational status before and during the pandemic as I am a housewife, I quit my job, I worked from home, I worked part-time and there was no change in my job.~Physical activity: I do not have physical activity, I do my daily work at home, I do daily walks, I exercise regularly.~Pain status: Participants were questioned that their pain conditions before and during the pandemic were much worse, worse, a little bad, no change, a little good,  better, It was questioned as much better.
Study NCT04779593 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood Sample Complete blood count
Description: Blood Sample Complete blood count at D0, M6, M12, M18 and M24/end follow-up visit
Study NCT04779593 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood Sample Iron panel
Description: Blood Sample Iron panel (serum ferritin, serum iron and serum transferrin to determine transferrin saturation according to randomization group (at M6, M12 and M18) at D0, M6, M12, M18 and M24/end follow-up visit and at each bloodletting.
Study NCT04779593 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood Sample Iron panel
Description: Blood Sample Iron panel (serum ferritin, serum iron and serum transferrin to determine transferrin saturation according to randomization group (at M6, M12 and M18) at D0, M6, M12, M18 and M24/end follow-up visit and at each bloodletting.
Study NCT04963764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Participants will be randomized to receive oral amoxicillin for a standard course (10 days)
Study NCT04963764 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be randomized to receive oral placebo for a standard course (10 days)
Study NCT04779593 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood Sample Fasting Glucose
Description: Blood Sample Fasting Glucose at D0 and M24/end follow-up visit
Study NCT04779593 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood Sample Fasting Glucose
Description: Blood Sample Fasting Glucose at D0 and M24/end follow-up visit
Study NCT04779593 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample lipid panel
Description: Blood sample lipid panel (total cholesterol, triglycerides, HDL, LDL) at D0 and M24/end follow-up visit
Study NCT04779593 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample lipid panel
Description: Blood sample lipid panel (total cholesterol, triglycerides, HDL, LDL) at D0 and M24/end follow-up visit
Study NCT04779593 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample liver panel
Description: Blood sample liver panel (total bilirubin, Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma-Glutamyl Transferase) at D0 and M24/end follow-up visit
Study NCT04779593 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample liver panel
Description: Blood sample liver panel (total bilirubin, Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma-Glutamyl Transferase) at D0 and M24/end follow-up visit
Study NCT04779593 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample C reactive protein
Description: Blood sample C reactive protein at D0 and M24/end follow-up visit
Study NCT04779593 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample C reactive protein
Description: Blood sample C reactive protein at D0 and M24/end follow-up visit
Study NCT04779593 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bloodletting - control group
Description: Patients treated with bloodletting according to current guidelines (ferritin alone). Patient will undergo bloodletting with a goal of maintaining a serum ferritin equal or lower than 50 g/L according to current clinical practice guidelines (French and European).A first bloodletting will be performed at inclusion with the same volume as usually performed by the patients.Results of the biological test performed at this visit will guide the time schedule and volume of the next bloodletting according to randomization group. Time schedule and volume of bloodletting will be adjusted to biological results after each follow-up visit.
Study NCT04779593 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BioBank
Description: Blood sample will be collected for BioBank at D0, M12 and M24.
Study NCT04779593 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BioBank
Description: Blood sample will be collected for BioBank at D0, M12 and M24.
Study NCT04779593 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medico-economical
Description: Medico-economic data will be collected at each follow up visit.
Study NCT06442813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EFT GROUP
Description: One times one pregnancy
Study NCT04603807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib
Description: Entrectinib will be self-administered orally at a dose of 600 mg (three 200 mg capsules per day) once daily with or without food.
Study NCT04603807 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crizotinib
Description: Crizotinib will be self-administered orally at a dose of 250 mg twice daily with or without food.
Study NCT04654325 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: conjunctival swab
Description: Patients will have conjunctival swab for SARS-CV-2 genome detection
Study NCT04779593 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medico-economical
Description: Medico-economic data will be collected at each follow up visit.
Study NCT04779593 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bloodletting - experimental group
Description: Patients treated with bloodletting according to transferrin saturation and serum ferritin. Patients will undergo bloodletting with a goal of maintaining a serum transferrin saturation equal or lower than 50 % and a serum ferritin lower than the upper limit of the normal range (300 g/L for men and 200 g/L for women).A first bloodletting will be performed at inclusion with the same volume as usually performed by the patients.Results of the biological test performed at this visit will guide the time schedule and volume of the next bloodletting according to randomization group. Time schedule and volume of bloodletting will be adjusted to biological results after each follow-up visit.
Study NCT05301231 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Genomics (DNA Extraction)
Description: Blood samples for detection of:~Genes for Dyslipidemia BY WES and NGS (4 GWA) (30 cases) Genes polymorphism for NAFLD/NASH BY TaqMan SNP Genotyping Assay on 10 GWAS
Study NCT05301231 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Epi-genomics
Description: * blood samples for detection of Expression profiling of plasma microRNAs~* PCR array to determine the altered miRNAs for 168 plasma miRNAs (12 cases)~* Expression analysis of top 5 altered miRNAs (All)
Study NCT05301231 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Proteomics (Glycoproteomics)
Description: blood samples for Identifying glycosylation pattern of five glycoproteins linked with NAFLD/NASH (transferrin, apoC III, haptoglobin, Mac2 binding protein, IgG)
Study NCT05301231 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Salivary Metabolomics
Description: Salivary Samples for detecting Salivary Metabolomics~1. Genome analysis (Identification of microbial strains common among Egyptians BY apid RT-PCR (DNA sequencing: 16S rRNA gene amplicons)~2. Microbiome related Metabolites Identification using GC-MS Analysis (the top 5 identified microbial-related metabolites) as metabolomics~3. Meta-genomic assess of three microbiome-related metabolites; lactoferrin, (LPS), (IgA) BY Commercial ELISA kits
Study NCT05301231 — intervention group
Intervention type: BEHAVIORAL
Intervention: Individualized counselling for behavioural modification
Description: Individualized counselling for behavioral modification (3 sessions):~Nutritional education, Promotion of physical activities and Cognitive \& Psychological support
Study NCT05672537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500mg intravenous injection for 21d cycle
Study NCT04838392 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RIGHTEST Continuous Glucose Monitoring System
Description: RIGHTEST Continuous Glucose Monitoring System
Study NCT04862858 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: The educational intervention will involve guideline-based treatment recommendation information for providers via fax/mail and phone and provide resources via mail and phone for patients to learn more about ways to reduce their cardiovascular risk.
Study NCT05415891 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Health Policy Project (HPP) HIV-Stigma and Discrimination Reduction Training Curriculum
Description: The Health Policy Project (HPP) training curriculum provides participatory training modules that address three key actionable drivers of HIV-stigma. The HPP curriculum was adapted through participatory workshops with the study's community collaborative board, including representatives from the HIV care and advocacy communities as well as community members. The training is a whole-site training to address stigma as a barrier to accessing substance use and mental health services by persons living with HIV. Consequently, staff at all levels (clinical and nonclinical) will be trained on stigma and discrimination as it relates to persons living with HIV in order to reduce stigma-related barriers to mental health and substance use healthcare in Positive Impact Health Centers and increase retention in healthcare services for persons living with HIV.
Study NCT05415891 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: You℞ Decision prescribing platform
Description: The You℞ Decision prescribing platform is a mobile application that serves as a reference to quickly inform providers about the medications recommended for serious mental health disorders and naltrexone to treat AUD; the appropriate dosing regimen; and potential contraindications or interactions related to antiretroviral therapy medications or other psychiatric medication. Information for the platform is adapted from the Department of Veteran Affairs' Manual for HIV Care in Primary Care settings.
Study NCT06185244 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist-supported internet-delivered trauma-focused CBT
Description: 12 weeks of therapist-supported internet-delivered trauma-focused CBT for both the youth and the care giver.
Study NCT06185244 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 12 weeks of therapist-supported internet-delivered psychoeducation and stress management/relaxation for both the youth and the care giver.
Description: 12 weeks of therapist-supported internet-delivered psychoeducation and stress management/relaxation for both the youth and the care giver.
Study NCT05397444 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study with no intervention.
Study NCT04364191 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent Behavioral Sleep Intervention for Insomnia
Description: The MBSI-I will include a meaningful activity protocol during the day and ART therapy at night.
Study NCT04364191 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: The sleep hygiene educational material represents an active control intervention and is recommended as part of the initial treatment of insomnia based on an NIH guide for sleep education.
Study NCT05672537 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery
Study NCT04860349 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: 4-weeks of high intensity interval training, 3 sessions/week on alternate days. each session for 20 minutes, excluding the warm-up and cool-down.
Study NCT05672537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: gemcitabine 1000mg/m2, D1\&D8, 21d cycle.
Study NCT05672537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: cisplatin 25mg/m2, D1\&D8, 21d cycle.
Study NCT06418035 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video modeling by scanning Qr code
Description: The protocol activity carried out by the experimental group will involve the use of the QR Code: in the operator's presence, the child scans the code through a technological device and watches the video of the activity to be played later in the HomeLab.
Study NCT06418035 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Modeling traditional method
Description: The control group will carry out the protocol activities in a traditional way, without technological tools. The child observes the operator who shows the live activity inside the HomeLab.
Study NCT06070233 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: stereotactic radiosurgery (SRS) dorsal root rhizotomy radiomodulation
Description: Patients will be simulated in the supine position in an immobilization apparatus deemed by the treating physician to be appropriate for the patient being able to comfortably maintain position for the duration of treatment. All patients will be simulated and treated using free breathing. Prescription dose is 50 Gy delivered in a single fraction to the target volume, prescribed to whatever isodose line produces optimal falloff (but not less than a 50% isodose line; dmax \<100Gy) .~All radiosurgery treatment will utilize the Varian Edge, Varian TrueBeam STx, or CyberKnife system
Study NCT06070233 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Patients will be simulated in the supine position in an immobilization apparatus deemed by the treating physician to be appropriate for the patient being able to comfortably maintain position for the duration of treatment. All patients will be simulated and treated using free breathing.
Study NCT06595342 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: no intervention
Study NCT06504576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol 50 MG Oral Tablet
Description: Two consecutive weeks of Cilostazol (50mg BID) two days after admission
Study NCT05157789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS
Description: In the study, text message will be sent to relatives of the patients for informing and the effect will be determine on the level of anxiety during cardiovascular surgery.
Study NCT06504576 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional internal medicine treatment
Description: Receives only conventional internal medicine treatment
Study NCT04934319 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance and Proprioceptive Training
Description: * Step-by-step training (5 levels)~* 30 minute per training~* 3 times per week~* Four weeks
Study NCT05448235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional treatment
Description: the patient will be asked to make pursed lip breathing (Breathe in for 2 seconds through his nose and Breathe out for 4 seconds through pursed lips)for 5-10 min ,3-4 times , 8-10 rep each cycle then asked to make diaphragmatic breathing exercise (Lie on his/her back and Inhale deeply through his/her nose for a count of three)for 5-10 min , 3-4 times , 8-10 repetition then postural drainage , furthermore the patient takes different position (prone to make percussion on lower lobes, side lying on anterior basal segment then sitting position on the upper lobe). After that a vibration on the chest (place a flat hand firmly atop the lung segment to be drained., and should apply light pressure and create a rapid, shaking movement) 1 min inhale and 5 time of repetition at the exhale and finally asked the patient to make productive cough for 5 times to get out the sputum.
Study NCT05448235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: thoracic mobilization
Description: we will use A SNAG to mobilization using type 3 oscillatory and sustain for 90 second, at first put the patient in 3 position (side lying to make mobilization of upper 6 ribs in downward direction then make on lower 6 ribs ,furthermore flexion of the thoracic and next rotation toward the midline then ask the patient to transfer to supine lying position and mobilize the sternum in downward direction the next mobilize the clavicle and ask the patient to take sitting position and put his hand on his head in adduction position and make extension on the thoracic vertebrae with inward mobilize with the investigator knees ,take each 4 vertebrae along the 12 thoracic vertebrae.
Study NCT06618092 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Relisten
Description: Patients will be attended using Relisten
Study NCT06620939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel Intrauterine System (LNG-IUS)
Description: Participants in the intervention group will receive Mirena placement after hysteroscopic polypectomy
Study NCT05539937 — intervention group
Intervention type: OTHER
Intervention: Quality of life questionnaire
Description: Before TAVI, 30 days, 6 months and twelve months after TAVI, patients will answer TASQ questionnaire,
Study NCT06314633 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hair cut
Description: Hair locks and follicles will be cut twice in winter and spring
Study NCT06481072 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital patient education
Description: This educative intervention includes both medical and psychological explanations, as well as basic strategies to manage pediatric FAPD. The medical information spans the topics of pain, functional abdominal pain and general advice in terms of child health, and the psychological information is based on cognitive-behavioural and pain management theoretical approaches. The intervention consists of six short, animated films with a total run-time of approximately 30 minutes. The films each cover one of the following topics; Why and how do we feel pain? What is functional abdominal pain? How to help: general advice, Thoughts, feelings and behaviour, Goals and strategies. The films are accessed by the patient via 1177.se and maintained on the SoB (Stöd- och behandling) platform that is recognised by the care provider as meeting current safety criteria and standards.
Study NCT06481072 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital patient education and iCBT
Description: This includes the educative intervention and a fully digital, four session version of the Aim to Decrease Anxiety and Pain Treatment (ADAPT), a CBT treatment program for FAPD. The treatment focuses on pain-management through the following core elements; The Pain-Gate Theory, breathing and relaxation strategies, calming statements, activity pacing, problem solving and behavior activation. This intervention is also accessed by the patient via 1177.se and maintained on the SoB (Stöd- och behandling) platform.
Study NCT06306144 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: Arm 1 : Psychoeducation aims to inform patients about post-stroke cognitive impairment, teach them coping strategies to compensate for these difficulties, provide information on symptom recognition and management, and offer emotional and psychological support to help them meet the challenges associated with these potential cognitive impairments.
Study NCT06314633 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Socio-economic questionnaires
Description: Information about parents education levels and professional occupation, geographic area, children gender, indoor and outdoor children's environmental exposures
Study NCT05412485 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Robotic assisted gait training
Description: Robotic assisted gait training is advanced technology used in the rehabilitation of neurological injuries and conditions like spinal cord injury, brain injury, stroke, multiple sclerosis, Parkinson's, cerebral palsy. It provides a repetitive task-specific motor training and modulates afferent input to spinal cord to generate rhythmic gait patterns that may be transformed to overground walking. The intensive repetitions of the rhythmic stepping movement during the training stimulates dependent plasticity and it may lead to brain reorganization. It facilitates cortical neural activities associated with motor control of walking.